What the other players in carotid stenting actually offer, and why that matters for InspireMD’s position
⚠️ Reader notice: The author holds a position or has active interest in NSPR at the time of writing. Nothing in this article constitutes financial advice. All analysis is based on publicly available information. Do your own due diligence. ⚠️
Before you can believe that CGuard Prime is genuinely best-in-class, you need to understand what it is actually being compared against.
That is a fair ask. “Best-in-class” is one of the most overused phrases in medtech. Every company with an FDA-approved device claims it. Most of the time, the claim starts to weaken the moment you look at the clinical data, the engineering trade-offs, and the actual competitive landscape.
In InspireMD’s case, I do not think it weakens. But understanding why requires looking more carefully at what the current carotid stenting market really offers, and what problem it still may not have fully solved.
The Market InspireMD Entered
The carotid stenting market is not new. Devices have been FDA-approved for transfemoral carotid artery stenting since the early 2000s. The main established players entering 2025 included Abbott Vascular, Medtronic, and, outside the US, a broader group of companies such as Terumo and others with long-standing vascular franchises.
Abbott’s Xact carotid stent system is one of the most established transfemoral CAS devices in the US market. It is a self-expanding nitinol stent with a long operating history, wide physician familiarity, and a recognized clinical record. It works.
That matters. Established devices do not survive in vascular intervention unless they solve a real need reliably enough to remain trusted in practice.
But the central issue with Xact, and more broadly with earlier-generation carotid stenting systems, is not that they fail to function. It is that embolic protection is still largely handled by a separate mechanism rather than by the stent architecture itself.
The Architecture Of The Problem
That distinction matters more than it may first appear.
In a traditional carotid artery stenting procedure, the physician typically deploys a separate embolic protection device, often a distal filter or another protection strategy, before placing the stent. The purpose is straightforward: capture debris that may be released during the intervention and reduce the risk of embolic complications.
That approach can work. It has worked for years. But it is still, structurally, a layered solution rather than a single integrated one.
The stent opens the vessel. The protection device is meant to catch what may break loose during the process. Once the procedure is complete, the protection device is removed.
The issue is not that this model never works. The issue is that it may not fully solve the embolic problem at the level of the implant itself.
Protection devices do not necessarily capture everything. Retrieval itself may introduce risk. And the underlying stent architecture in conventional open-cell or closed-cell designs does not permanently prevent plaque material from interacting with the vessel lumen after the procedure is over.
That is the problem CGuard Prime appears to have been designed to address more directly, not by improving a separate protection tool, but by changing the architecture of the implant itself.
What MicroNet Actually Does Differently
This is where CGuard Prime becomes more interesting.
Its MicroNet is not a separate embolic protection device. It is not an add-on deployed upstream or retrieved at the end of the case. It is a fine polymer mesh integrated onto the external surface of the stent.
That does not make embolic risk disappear. No device does that. But it does represent a different engineering approach.
Instead of relying primarily on a temporary protection mechanism during the procedure, CGuard is built around the idea of maintaining plaque coverage at the level of the implant itself, including after the intervention is complete. In other words, the protective concept is embedded into the stent rather than outsourced to a separate procedural step.
That architectural distinction is one reason the device has drawn attention for years, and the clinical results are part of why that attention has persisted.
In the C-GUARDIANS pivotal trial, CGuard Prime reported a 30-day major adverse event rate of 0.95% and a 1-year rate of 1.93%.
These are results that the company and many observers have highlighted as exceptional in the context of carotid stenting. The study was peer-reviewed and published in the Journal of the American College of Cardiology in January 2026.
That matters because it moves the discussion beyond product positioning and into published clinical evidence.
There is also comparative real-world data that supports the idea that the design may matter in practice. In one two-center study comparing CGuard against the Carotid Wallstent, the CGuard cohort experienced no clinical complications, versus a 2.96% rate in the Wallstent group. That does not settle the category on its own, but it is a meaningful data point when viewed alongside the broader body of evidence.
The One Competitor Worth Naming Directly
The most intellectually honest way to look at this market is to acknowledge that CGuard is not the only device trying to improve the architecture of carotid stenting.
There is one competitor in particular that deserves to be named clearly: Terumo’s ROADSAVER Carotid Stent System.
ROADSAVER also uses a dual-layer concept and is designed around the idea that embolic protection should be addressed more directly through the implant architecture. On paper, it is the closest structural competitor to CGuard Prime in the category.
That matters because it helps clarify the real competitive question. The choice is no longer just between CGuard and older-generation carotid stents. It is also about whether InspireMD’s version of this next-generation design has a defensible clinical and strategic lead.
Two things stand out.
First, ROADSAVER has existed in Europe for years, and CGuard has coexisted in that environment while building a substantial real-world implant base.
That does not prove superiority by itself, but it does suggest that the market did not simply converge on one obvious winner and erase CGuard’s relevance.
Second, and more importantly, CGuard Prime appears to have the stronger FDA-grade pivotal evidence package.
Architecture alone is not enough in medtech. What matters is whether the device can translate design logic into clinical outcomes that regulators, physicians, and acquirers can take seriously.
On that front, CGuard currently appears to have an advantage.
Why The Competitive Landscape Still Supports The Thesis
This is where I think the competitive analysis becomes more interesting, not less.
The existence of a device like ROADSAVER does not necessarily weaken the InspireMD thesis. In some ways, it may strengthen it.
If more than one company is moving toward dual-layer or mesh-based carotid stent designs, that suggests the category itself may be converging around a shared conclusion: that integrated plaque coverage and more persistent embolic protection may represent a better long-term direction than conventional stent architecture alone.
That does not mean CGuard automatically wins. It does mean that InspireMD may have been early in recognizing where the category was going.
And being early matters when it is paired with something more durable:
- meaningful real-world implant experience,
- a PMA approval,
- and published clinical data that appear unusually strong for the category.
That combination gives InspireMD a real position. Not an untouchable one, but a real one.
The Part The Market May Be Underestimating
What I think the market may still be underestimating is not just that CGuard has a differentiated device.
It is that competitive advantage in medtech is often most valuable during the period when a product is both clearly differentiated and not yet broadly replicated.
That window does not stay open forever.
If dual-layer or mesh-based solutions continue to gain validation, larger competitors will keep investing. Commercial organizations with broader reach will keep adapting. Over a multi-year horizon, manufacturing and design advantages that look difficult to replicate today may become less exclusive.
That does not erase CGuard’s lead. It may simply mean that the strategic value of that lead is highest while the differentiation still feels clear.
And that is the part I think deserves more attention.
Whether the eventual outcome is independent scale, partnership, broader distribution leverage, or eventual consolidation, competitive windows in medtech tend to matter most while they are still visibly open.
Final Thought
This is why I do not think the competitive landscape weakens the thesis.
It complicates it, which is different.
CGuard is not entering an empty category. It is entering a real market with established operators, trusted legacy devices, and at least one next-generation competitor with overlapping design logic.
But that is exactly why the current data matters.
If InspireMD had an interesting concept and no serious comparison point, the story would be easier to tell but harder to trust. The fact that there are real alternatives, and that CGuard still appears differentiated on architecture, evidence, and commercial timing, is one reason I take the thesis seriously.
Competition does not invalidate the opportunity. It defines it.
Next in the series: ‘Why Boston Scientific (BSX) Could Be The Logical Buyer of InspireMD (NSPR)’, the strategic logic behind a plausible acquirer in medtech, and why the fit is hard to ignore.
🟢 Disclosure: The author holds a position or has active interest in this name.
⚠️ I produce these analyses for my own enjoyment and because I’m always looking for new opportunities. I am not a financial professional, and I don’t have access to professional-grade tools or proprietary data. Everything here is built from publicly available information and my own reasoning — which means I can be wrong. I may not always see the full picture, and my views will change as new information emerges or as I come to understand data points I initially overlooked or underweighted. I only operate with cash positions — no leverage, no margin, no shorting. I never bet against the market or individual companies. My analysis reflects the company’s fundamentals, not its price action. The company is not its price, and the price is not the company. I express my own opinions. I am not receiving compensation to share this. I have no business relationship with any company whose stock is mentioned in this article. Nothing here is financial advice. Do your own due diligence.